Imatinib (STI571)

Catalog No.S2475 Synonyms: CGP057148B, ST-1571

Imatinib (STI571) Chemical Structure

Molecular Weight(MW): 493.6

Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.

Size Price Stock Quantity  
USD 70 In stock
USD 120 In stock
Bulk Discount

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 35 Publications

6 Customer Reviews

  • Ba/F3-p210T315I cells were treated with indicated concentrations of imatinib with or without PDMP for 24 h. Apoptosis was determined as in A. Data are shown as percentage of sub-G1 for apoptosis in triplicate cultures. *P<0.05.

    FASEB J 2011 25, 3661-3673. Imatinib (STI571) purchased from Selleck.

    Targeting KITLG through c-KIT inhibition using Imatinib; one representative experiment is shown (n = 4).

    Oncotarget, 2016, 7(34):54583-54595. Imatinib (STI571) purchased from Selleck.

  •  

    Inhibition of thymidine (a and b) and cytarabine (c and d) uptake with imatinib. K562 cells (a and c) and MEG-01 cells (b and d) were incubated at 37 ◦C for 15 min with imatinib transport buffer, and then incubated with 0.5 Ci of [3H] thymidine or [3H] cytarabine for an additional 5 min in presence of imatinib. Cells were then washed 3 times, lysed and radioactivity associated to cell pellets was quantified. DMSO, dimethylsulfoxide; DPD, dipyridamole.

    Leukemia Res 2012 36, 1311-1314. Imatinib (STI571) purchased from Selleck.

    ZFX regulates imatinib sensitivity and PI3K/Akt signaling pathway in CML cells. Viability of cells transfected with si-ZFX at the indicated doses of imatinib for 24 h (a). Colonies of leukemia cells and imatinib-resistant cells transfected with si-ZFX following treatment with imatinib for 10 days (b). Western blot analysis of Akt, p-Akt, CyclinD1, CyclinE1, Bcl-2, and Caspase-3 in K562 and K562/G01 cells transfected with si-ZFX for 2 days (c). The relative densities of proteins were quantified and normalized to b-Actin (d). Values represented the mean ± SD data from experiments in triplicate. *P\0.05 and **P\0.01

    Cell Biochem Biophys, 2016, 74(2):277-83. Imatinib (STI571) purchased from Selleck.

  • Cell Viability assay results. A2C12, BetaD5, GammaA3, GammaD12, A549, CaCo2, HepG2 cell lines were treated with imatinib mesylate for 24h and 96h.

    Dr. Thomas Kruwel of Fraunhofer. Imatinib (STI571) purchased from Selleck.

    A. Viability curve for the c-Kit mutant MelMS melanoma cell line treated with increasing concentrations of imatinib for 72h (relative to DMSO-treated controls; mean ±sd; n=3) B. MelMS melanoma cells were treated with 50nM imatinib for 24h. The effects on c-Kit, ERK and AKT activation were determined by immunoblotting.

    Dr. Helen Rizos from the university of Sydney. Imatinib (STI571) purchased from Selleck.

Purity & Quality Control

Choose Selective PDGFR Inhibitors

Biological Activity

Description Imatinib (STI571) is a multi-target inhibitor of tyrosine kinase with inhibition for v-Abl, c-Kit and PDGFR, IC50 values are 0.6 μM, 0.1 μM and 0.1 μM in cell-free or cell-based assays, respectively.
Targets
PDGFR [1]
(Cell-free assay)
c-Kit [2]
(M-07e cells)
v-Abl [1]
(Cell-free assay)
100 nM 100 nM 600 nM
In vitro

In vitro assays for inhibition of a panel of tyrosine and serine/threonine protein kinases show that Imatinib inhibits the v-Abl tyrosine kinase and PDGFR potently with an IC50 of 0.6 and 0.1 μM, respectively. [1] Imatinib inhibits the SLF-dependent activation of wild-type c-kit kinase activity with a IC50 for these effects of approximately 0.1 μM, which is similar to the concentration required for inhibition of PDGFR. [2] Imatinib exhibits growth-inhibitory activity on the human bronchial carcinoid cell line NCI-H727 and the human pancreatic carcinoid cell line BON-1 with an IC50 of 32.4 and 32.8 μM, respectively. [3] A recent study shows that Imatinib has the potential to exert its antileukemia effects in chronic myelogenous leukemia by down-regulating hERG1 K(+) channels, which are highly expressed in leukemia cells and appear of exceptional importance in favoring leukemogenesis. [4]

Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
LAMA-84 Mnq0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVXJR|UxRTBwMEezNFQh|ryP MXzTRW5ITVJ?
EM-2 NED0bYJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MoDVTWM2OD1yLkC4PFgh|ryP MlfHV2FPT0WU
MEG-01 NXTteG5tT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWTVfYxIUUN3ME2wMlA5QTJzIN88US=> MXvTRW5ITVJ?
BV-173 NULKe2xiT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1PlW2lEPTB;MD6xPFc1KM7:TR?= MXHTRW5ITVJ?
K-562 NG\SeoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGL1RpVKSzVyPUCuNlI1OzJizszN NF;pdWdUSU6JRWK=
CGTH-W-1 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PEcmlEPTB;MD6zPFM4PCEQvF2= MYDTRW5ITVJ?
ST486 M2jKS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3KTWM2OD1yLk[4OVQh|ryP MlzBV2FPT0WU
NCI-H1436 NFHPNYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIfDZXJKSzVyPUCuPVc5ODFizszN MljmV2FPT0WU
NOS-1 NEfhdZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVTJR|UxRTFwNkWzPFMh|ryP NITrTXNUSU6JRWK=
A498 NEPmSIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFfsNGlKSzVyPUKuOVczOjNizszN Ml;LV2FPT0WU
BE-13 NYrZcGlXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXu5c4FpUUN3ME2yMlYzOTB4IN88US=> NIn2WmRUSU6JRWK=
SUP-T1 Mn\MS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFnJfXlKSzVyPUOuPFI6ODdizszN MnPwV2FPT0WU
NCI-H1770 NEO1WHhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXnJW5lRUUN3ME21MlU4OjZ{IN88US=> MX;TRW5ITVJ?
IMR-5 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MnrnTWM2OD14LkKyNVQ4KM7:TR?= NVu2R5AzW0GQR1XS
LB2241-RCC M{LmRWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlLvTWM2OD16LkC3N|g1KM7:TR?= M4XHdnNCVkeHUh?=
TGBC24TKB MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEjhb5BKSzVyPUiuN|QxPTJizszN MlzJV2FPT0WU
SCC-15 MoTyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWHJR|UxRTFyLke3PFgh|ryP NWLRbYQzW0GQR1XS
BB49-HNC NHe0WXBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3e3bWlEPTB;MUSuN|M{PSEQvF2= NHfJXIpUSU6JRWK=
ES7 NVPpVmVwT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELzd5hKSzVyPUG0Mlc{PzlizszN NWjiSZB5W0GQR1XS
LB2518-MEL M1[xZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\ueWJEUUN3ME2xOk43ODl2IN88US=> NF3JS3JUSU6JRWK=
NCI-H510A NIL0fplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXj4eY1nUUN3ME2xO{4zPDR{IN88US=> NEDyeYlUSU6JRWK=
TE-441-T NYLEV|Z{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX;JR|UxRTF5LkK4PFYh|ryP M{DJW3NCVkeHUh?=
HH MnvpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NI\OVI5KSzVyPUG3MlM6QTlizszN MoriV2FPT0WU
LC4-1 NYjBcIc1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHPwZ4pKSzVyPUG4MlA3PTJizszN Mo\kV2FPT0WU
KARPAS-45 NVzCepVPT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYPt[ZJXUUN3ME2xPE4yQDR6IN88US=> NYfab5E3W0GQR1XS
LB1047-RCC NYDsPIdtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmPGTWM2OD1zOD60OFUzKM7:TR?= MV3TRW5ITVJ?
NKM-1 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmH5TWM2OD1zOT6zOVUzKM7:TR?= MoGzV2FPT0WU
SCLC-21H Mle0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1m2SWlEPTB;MkCuNVI1PiEQvF2= NVTCWnJJW0GQR1XS
RS4-11 MlHCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4\kTGlEPTB;MkCuN|MxQCEQvF2= MnrpV2FPT0WU
ALL-PO NIfUV|hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXW5PVViUUN3ME2yNE45OTR7IN88US=> M3PVeXNCVkeHUh?=
GDM-1 NXzVd3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnzyTWM2OD1{Mj61PVQ2KM7:TR?= MnW4V2FPT0WU
DMS-79 NVfO[HpTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnfVTWM2OD1{ND60PVM1KM7:TR?= MnPYV2FPT0WU
MPP-89 Mn\nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWXJR|UxRTJ3Lk[4O|Qh|ryP NF23UHBUSU6JRWK=
NB10 NUfw[GpQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGLkc4NKSzVyPUK2MlQ3QTlizszN NV;GO4x{W0GQR1XS
LS-513 NX3jSYhTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEfPU4JKSzVyPUK2Mlg5PDdizszN MlXZV2FPT0WU
L-540 NVvLOWhGT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2LZZmlEPTB;Mk[uPVE1OyEQvF2= NX\1blgyW0GQR1XS
ES1 MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4jvS2lEPTB;MkeuOVIyKM7:TR?= NWXjcW14W0GQR1XS
NTERA-S-cl-D1 NI\sWmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXDTWM2OD1|MD61NFk{KM7:TR?= NV;YUVZmW0GQR1XS
EW-1 M2PoVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3vqO2lEPTB;M{KuPVQ2PCEQvF2= M2DQXHNCVkeHUh?=
Calu-6 NV7zT4FyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFPhXoZKSzVyPUOzMlE5PTVizszN M1X6bnNCVkeHUh?=
CTV-1 MlfnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlrqTWM2OD1|Mz65O|g6KM7:TR?= M1:wOnNCVkeHUh?=
YT NWLae3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWPDW|lXUUN3ME2zPE42OjB7IN88US=> MmDIV2FPT0WU
TE-6 MlWyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mmf5TWM2OD12MT6yO|k5KM7:TR?= MV\TRW5ITVJ?
HT-144 NETse3lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWnJR|UxRTRzLkW0PFYh|ryP NICze3FUSU6JRWK=
EW-13 NHXV[WFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmHGTWM2OD12Mj6yO|kyKM7:TR?= M33seHNCVkeHUh?=
KALS-1 M{TD[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Ml3PTWM2OD12Mz6xN|I6KM7:TR?= NV62fmV6W0GQR1XS
MOLT-16 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUfJR|UxRTR3LkC3OVIh|ryP NYPzfY9YW0GQR1XS
D-336MG MmnpS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fjcGlEPTB;NEWuPVU6QSEQvF2= NEK5V41USU6JRWK=
TE-11 MUfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXjUUmFlUUN3ME20Ok43PTNizszN MnHuV2FPT0WU
EB2 MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHW1XYZKSzVyPUS2MlY6QSEQvF2= NGDWR4tUSU6JRWK=
SK-N-DZ M1n2dWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFTITGJKSzVyPUS4MlA6PjFizszN NW\VNJlMW0GQR1XS
SW684 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1;4VmlEPTB;NEiuNlY6PSEQvF2= NYrtVZZ4W0GQR1XS
EW-18 NETr[pBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MUjJR|UxRTR6LkSzPVUh|ryP NVrqbJhUW0GQR1XS
RL95-2 MWnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXjJR|UxRTVyLkC3NUDPxE1? MoHsV2FPT0WU
CHP-126 MmnlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWfJR|UxRTVyLki5NFUh|ryP MlzYV2FPT0WU
NCI-H1395 Ml7OS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFG5WIFKSzVyPUWxMlc5OzVizszN M3i1fXNCVkeHUh?=
TE-15 NHrLeJZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVjJR|UxRTV{LkK1OVYh|ryP MkXTV2FPT0WU
ES4 NU\wc2JvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXjNUJkzUUN3ME21Nk46Pzd3IN88US=> NEH5ZZlUSU6JRWK=
TE-1 M171cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3hcWlSUUN3ME21N{46PDV3IN88US=> M3PxV3NCVkeHUh?=
SIMA NFXI[VVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX3JR|UxRTV5LkOzNVEh|ryP MYDTRW5ITVJ?
LB647-SCLC MknGS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFHRSWtKSzVyPU[0MlEyQDhizszN NIPoc4hUSU6JRWK=
KY821 NELMbnNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4\HNGlEPTB;NkSuNlU2OiEQvF2= MoHYV2FPT0WU
LC-2-ad MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXnJR|UxRTZ3Lke2NFEh|ryP M3\O[XNCVkeHUh?=
KP-N-RT-BM-1 M{jjVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIW3N2VKSzVyPU[2MlY{PjZizszN M4P2R3NCVkeHUh?=
SW872 NHrOUnlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUjyOFVvUUN3ME22O{41Ozh{IN88US=> NXf5bXBEW0GQR1XS
ES5 M{nDNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4LWTmlEPTB;NkeuOlk3QCEQvF2= Mkm4V2FPT0WU
SK-NEP-1 M13KXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVTJR|UxRTZ6LkO4NFMh|ryP M3K4cXNCVkeHUh?=
RPMI-6666 NYnVRoh2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MojvTWM2OD15MT6wN|Ih|ryP MoHYV2FPT0WU
UACC-812 M1\CeWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWjJR|UxRTdzLkG2NFkh|ryP MVnTRW5ITVJ?
COLO-829 NFm3OIVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDUPFQyUUN3ME23Nk43QTh5IN88US=> M4nBOnNCVkeHUh?=
KP-N-YS MXXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NHy5dJpKSzVyPUeyMlcyOzlizszN MWHTRW5ITVJ?
GI-1 NHnwUmlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mmi0TWM2OD15Mz6yPFY5KM7:TR?= Mn;uV2FPT0WU
ETK-1 NI\KV4NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXrVU4x7UUN3ME23N{41QTN{IN88US=> MWrTRW5ITVJ?
LXF-289 NXnIXJg2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NEnsOmlKSzVyPUezMlczQSEQvF2= MnfNV2FPT0WU
CAS-1 M2n4d2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXntXJYzUUN3ME23N{45QDV5IN88US=> M3PVWnNCVkeHUh?=
EW-22 Mor4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmrjTWM2OD15ND63NVE2KM7:TR?= M3rifHNCVkeHUh?=
NCI-H2196 M{\TNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXnJR|UxRTd3Lk[zO|kh|ryP NV7IRWhbW0GQR1XS
EoL-1-cell NIS5[|lIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33idWlEPTB;OEGuOlk3OyEQvF2= MVXTRW5ITVJ?
D-247MG M1rYVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3nybmlEPTB;OEKuNFI1QCEQvF2= NUPje5psW0GQR1XS
Becker MkPOS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4HQfWlEPTB;OEKuN|Q5OSEQvF2= NV;RWHZUW0GQR1XS
IST-MEL1 NFjkSWlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmTiTWM2OD16Mj6zOFgzKM7:TR?= M4riXnNCVkeHUh?=
MDA-MB-134-VI M3LuPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PGUmlEPTB;OEKuOVk6PiEQvF2= MXvTRW5ITVJ?
NCI-H1092 M2\xe2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MknOTWM2OD16ND6wNVk4KM7:TR?= MknRV2FPT0WU
KINGS-1 MXTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3LsNGlEPTB;OE[uNVYyQCEQvF2= M17VS3NCVkeHUh?=
HCC2218 NYDTVIJ2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYGzbmRNUUN3ME24Ok44QTF|IN88US=> NVfPOHYzW0GQR1XS
GI-ME-N MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXLUOnJQUUN3ME24O{44Pjl7IN88US=> NVTFTI5LW0GQR1XS
AM-38 M2PmZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NV\0XFJYUUN3ME24PE4{QTV|IN88US=> MV3TRW5ITVJ?
KNS-42 Mn\CS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoS4TWM2OD16OT6xNFE5KM7:TR?= NUPOfpd{W0GQR1XS
C8166 MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4LQfWlEPTB;OEmuOlEzPSEQvF2= M3\3bHNCVkeHUh?=
Ramos-2G6-4C10 M1PVXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\BV5pjUUN3ME24PU45PzF7IN88US=> MUjTRW5ITVJ?
CTB-1 NFPaUGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NELBXGxKSzVyPUmwMlY{PTdizszN NYnIUllIW0GQR1XS
HCE-4 M1nqSmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MljaTWM2OD17MT6xN|M3KM7:TR?= M2XuNnNCVkeHUh?=
NCI-H526 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3XCb2lEPTB;OUKuOFExOyEQvF2= M1O3[3NCVkeHUh?=
ECC4 MmXhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fqZ2lEPTB;OUSuNlU2PSEQvF2= NIj3WmVUSU6JRWK=
NCCIT MWHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUe2e|NCUUN3ME25OU4{Ojl{IN88US=> MkLHV2FPT0WU
MZ7-mel MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHqTWM2OD17NT65NFQh|ryP NEnxWIJUSU6JRWK=
COLO-684 NGLRS3dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWTJR|UxRTl4LkKzPFUh|ryP MoX6V2FPT0WU
SU-DHL-1 NF;Oc5hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHfnfWtKSzVyPUm2Mlk5PDJizszN MYjTRW5ITVJ?
SF126 MljJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVPqZm55UUN3ME25O{42OjF5IN88US=> MlXRV2FPT0WU
NMC-G1 MYjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml3TTWM2OD17OD60OVU1KM7:TR?= MnfiV2FPT0WU
NB14 MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1rpXmlEPTB;OUiuPVIxQCEQvF2= NEfWSlJUSU6JRWK=
VA-ES-BJ MUXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVfnSW51UUN3ME25PU41ODV4IN88US=> NUHEepB6W0GQR1XS

... Click to View More Cell Line Experimental Data

In vivo Imatinib produces a different antitumor effect on three xenografted tumors derived from surgical samples of fresh human small cell lung cancers, with 80%, 40% and 78% growth inhibition of SCLC6, SCLC61 and SCLC108 tumors, respectively, and no significant inhibition of SCLC74 growth. [5] In high fat fed ApoE(-/-) mice, Imatinib significantly reduces the high fat-induced lipid staining area by 30%, 27% and 35% compared to high-fat diet untreated controls when dosed by gavage at 10, 20 and 40 mg/kg, respectively, and suppresses carotid artery lipid accumulation. [6]

Protocol

Kinase Assay:

[1]

+ Expand

PDGF receptor kinase activity:

PDGF receptor is immunoprecipitated from BALB/c 3T3 cell extracts with rabbit antiserum to the murine PDGF receptor for 2 hours on ice. Protein A-Sepharose beads are used to collect the antigen-antibody complexes. The immunoprecipitates are washed twice with TNET (50 mM Tris, pH 7.5, 140 mM NaCl, 5 mM EDTA, 1% Triton X-100), once with TNE (50 mM Tris, pH 7.5, 140 mM EDTA), and once with kinase buffer (20 mM Tris, pH 7.5,10 mM MgCl2). After stimulation with PDGF (50 ng/mL) for 10 minutes at 4 °C, different concentrations of drug are added to the reaction mixture. PDGF receptor kinase activity is determined by incubation with 10 μCi [7-33P]-ATP and l μM ATP for 10 minutes at 4 °C. Immune complexes are separated by SDS-PAGE on 7.5% gels.
Cell Research:

[3]

+ Expand
  • Cell lines: BON-1 cells and NCI-H727 cells
  • Concentrations: ~100 μM
  • Incubation Time: 48 hours
  • Method:

    BON-1 cells and NCI-H727 cells are seeded into flat-bottomed 96-well plates in triplicate and allowed to adhere overnight in 10% fetal bovine serum-supplemented DMEM or RPMI 1640 complete medium, respectively; the medium is then exchanged for serum-free medium (negative control) or serum-free medium containing serial dilutions of Imatinib. After 48 hours (control cultures do not reach confluence), the number of metabolically active cells is determined by the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide assay, and absorbance is measured in a Packard Spectra microplate reader at 540 nm. Growth inhibition is calculated using the following formula: inhibition rate = (1 − a / b) × 100%, where a and b are the absorbance values of the treated and control groups, respectively.


    (Only for Reference)
Animal Research:

[5]

+ Expand
  • Animal Models: SCLC6, SCLC61, SCLC 74 and SCLC108 small cell lung cancers are injected into Swiss mice (nu/nu, female).
  • Formulation: Imatinib is diluted in water.
  • Dosages: 70 or 100 mg/kg
  • Administration: Administered via i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 33 mg/mL (66.85 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order:
2% DMSO+30% PEG 300+2% Tween 80+ddH2O
For best results, use promptly after mixing.
2mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 493.6
Formula

C29H31N7O

CAS No. 152459-95-5
Storage powder
in solvent
Synonyms CGP057148B, ST-1571

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT00044304 Recruiting Hypereosinophilic Syndrome National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) August 22, 2002 Phase 2
NCT02644525 Not yet recruiting Loaisis National Institute of Allergy and Infectious Diseases (NIAID)|National Institutes of Health Clinical Center (CC) December 21, 2015 Phase 2
NCT03007147 Not yet recruiting B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1|BCR-ABL1 Fusion Protein Expression|Minimal Residual Disease|Philadelphia Chromosome Positive|T Acute Lymphoblastic Leukemia|Untreated Adult Acute Lymphoblastic Leukemia|Untreated Childhood Acute Lymphoblastic Leukemia Childrens Oncology Group|National Cancer Institute (NCI) July 2017 Phase 3
NCT03023046 Not yet recruiting Adult Acute Lymphoblastic Leukemia|Adult Lymphoblastic Lymphoma|CD20 Positive|Philadelphia Chromosome Positive University of Washington|National Cancer Institute (NCI) February 2017 Phase 2
NCT02538926 Not yet recruiting B Acute Lymphoblastic Leukemia|B Lymphoblastic Lymphoma|Recurrent Adult Acute Lymphoblastic Leukemia|Recurrent B Lymphoblastic Lymphoma|Recurrent T Lymphoblastic Leukemia/Lymphoma|Refractory B Lymphoblastic Lymphoma|Refractory T Lymphoblastic Lymphoma|T Acute Lymphoblastic Leukemia|T Lymphoblastic Lymphoma University of Washington|National Cancer Institute (NCI) January 2017 Phase 2
NCT02924714 Recruiting Gastrointestinal Stromal Tumor Oslo University Hospital January 2017 Phase 2

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field

Frequently Asked Questions

  • Question 1:

    Could you please advise whether it is a clear solution for compound dissolved in vehicle 2% DMSO+30% PEG 300+2% Tween 80+ddH2O?

  • Answer:

    For S2475 Imatinib (STI571), it is soluble in 2% DMSO+30% PEG 300+2% Tween 80+ddH2O at 2mg/ml. When making the solution, please dissolve the compound in DMSO clearly first. If it dissolves not readily, please sonicate and warm it in water bath at 45-50C. Then add PEG and Tween. After they mixed well, dilute with water.

  • Question 2:

    What is the difference between S2475 (Imatinib) and S1026 (Imatinib Mesylate)? Are they water soluble?

  • Answer:

    S2475 is free base of Imatinib while S1026 is a solt form of Imatinib. They have exactly the same biological activity but different solubility. S1026 can be dissolved in water, but S2475 is not soluble in water. S2475 can be dissolved in DMSO at up to 3mg/ml.

Related Antibodies

PDGFR Signaling Pathway Map

PDGFR Inhibitors with Unique Features

Related PDGFR Products

Tags: buy Imatinib (STI571) | Imatinib (STI571) supplier | purchase Imatinib (STI571) | Imatinib (STI571) cost | Imatinib (STI571) manufacturer | order Imatinib (STI571) | Imatinib (STI571) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID